Immune recovery study for CMML patients after stem cell transplant
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how the immune system recovers after a stem cell transplant in people with chronic myelomonocytic leukemia (CMML). It aims to understand how this recovery affects health outcomes, which may help improve future care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with chronic myelomonocytic leukemia (CMML).
- You must have had a stem cell transplant (also called HSCT).
- You must have been treated at Peking University People's Hospital since January 1, 2005.
- You must not have conditions that would make it hard to keep up with follow-up appointments, like severe mental health issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is for adults who have had a stem cell transplant and now have their first CMV infection. It tests a way to measure your immune response to CMV, which may help doctors decide the best treatment for you.
This trial tests a chemotherapy regimen (thiotepa-containing preparation) combined with a stem cell transplant from a donor to treat chronic myelomonocytic leukemia (CMML), a rare blood cancer. The goal is to see if this approach helps patients with intermediate-to-high risk disease achieve remission.
This study looks at how your immune system “rebuilds” after certain cell-based cancer treatments or stem cell transplants. It may help researchers better understand why immune recovery differs between people and how to improve protection against infections.
This study looks at how your immune system recovers after a stem cell transplant and whether that affects your risk of getting a late cytomegalovirus (CMV) infection. You will take letermovir, a medicine that helps prevent CMV, and the study will check your immune function when you stop taking it.
This research study examines blood cells from patients with chronic myelomonocytic leukemia (CMML), a rare blood cancer, to better understand how the disease develops and progresses. By studying your blood cells, researchers hope to learn more about what causes CMML and how to treat it better.
This study uses a special score (immune risk score) to check how well your immune system rebuilds after a half-matched stem cell transplant. The goal is to find patients who might need extra help with immune recovery.
Hear when a new Chronic Myelomonocytic Leukemia (CMML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.